IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients

<p>Abstract</p> <p>The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent a...

Full description

Bibliographic Details
Main Authors: Sayre James, Koo Patrick, Cho Tiffany, Nguyen Caroline, Tong Jason, Weitzman Rachel, Mahanian Michelle, Tse Stephen, Magpantay Larry, Liu Philip T, Lourenco Elaine, Eskin Ascia, Liu Guanghao, Tse Eric, Chattopadhay Madhuri, La Cava Antonio, Fiala Milan, Martinez-Maza Otoniel, Rosenthal Mark J, Wiedau-Pazos Martina
Format: Article
Language:English
Published: BMC 2010-11-01
Series:Journal of Neuroinflammation
Online Access:http://www.jneuroinflammation.com/content/7/1/76
id doaj-e1c6177d1caa49d680f35cfcff10b082
record_format Article
spelling doaj-e1c6177d1caa49d680f35cfcff10b0822020-11-24T23:30:08ZengBMCJournal of Neuroinflammation1742-20942010-11-01717610.1186/1742-2094-7-76IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patientsSayre JamesKoo PatrickCho TiffanyNguyen CarolineTong JasonWeitzman RachelMahanian MichelleTse StephenMagpantay LarryLiu Philip TLourenco ElaineEskin AsciaLiu GuanghaoTse EricChattopadhay MadhuriLa Cava AntonioFiala MilanMartinez-Maza OtonielRosenthal Mark JWiedau-Pazos Martina<p>Abstract</p> <p>The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent assays (ELISAs) to measure the cytokine interleukin-17A (IL-17A) in the serum of ALS patients (n = 32; 28 sporadic ALS (sALS) and 4 familial ALS (fALS)) and control subjects (n = 14; 10 healthy subjects and 4 with autoimmune disorders). IL-17A serum concentrations were 5767 ± 2700 pg/ml (mean ± SEM) in sALS patients and 937 ± 927 pg/ml in fALS patients in comparison to 7 ± 2 pg/ml in control subjects without autoimmune disorders (p = 0.008 ALS patients vs. control subjects by Mann-Whitney test). Sixty-four percent of patients and no control subjects had IL-17A serum concentrations > 50 pg/ml (p = 0.003 ALS patients vs. healthy subjects by Fisher's exact test). The spinal cords of sALS (n = 8), but not control subjects (n = 4), were infiltrated by interleukin-1β- (IL-1β-), and tumor necrosis factor-α-positive macrophages (co-localizing with neurons), IL-17A-positive CD8 cells, and IL-17A-positive mast cells. Mononuclear cells treated with aggregated forms of wild type superoxide dismutase-1 (SOD-1) showed induction of the cytokines IL-1β, interleukin-6 (IL-6), and interleukin-23 (IL-23) that may be responsible for induction of IL-17A. In a microarray analysis of 28,869 genes, stimulation of peripheral blood mononuclear cells by mutant superoxide dismutase-1 induced four-fold higher transcripts of interleukin-1α (IL-1α), IL-6, CCL20, matrix metallopeptidase 1, and tissue factor pathway inhibitor 2 in mononuclear cells of patients as compared to controls, whereas the anti-inflammatory cytokine interleukin-10 (IL-10) was increased in mononuclear cells of control subjects. Aggregated wild type SOD-1 in sALS neurons could induce in mononuclear cells the cytokines inducing chronic inflammation in sALS spinal cord, in particular IL-6 and IL-17A, damaging neurons. Immune modulation of chronic inflammation may be a new approach to sALS.</p> http://www.jneuroinflammation.com/content/7/1/76
collection DOAJ
language English
format Article
sources DOAJ
author Sayre James
Koo Patrick
Cho Tiffany
Nguyen Caroline
Tong Jason
Weitzman Rachel
Mahanian Michelle
Tse Stephen
Magpantay Larry
Liu Philip T
Lourenco Elaine
Eskin Ascia
Liu Guanghao
Tse Eric
Chattopadhay Madhuri
La Cava Antonio
Fiala Milan
Martinez-Maza Otoniel
Rosenthal Mark J
Wiedau-Pazos Martina
spellingShingle Sayre James
Koo Patrick
Cho Tiffany
Nguyen Caroline
Tong Jason
Weitzman Rachel
Mahanian Michelle
Tse Stephen
Magpantay Larry
Liu Philip T
Lourenco Elaine
Eskin Ascia
Liu Guanghao
Tse Eric
Chattopadhay Madhuri
La Cava Antonio
Fiala Milan
Martinez-Maza Otoniel
Rosenthal Mark J
Wiedau-Pazos Martina
IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
Journal of Neuroinflammation
author_facet Sayre James
Koo Patrick
Cho Tiffany
Nguyen Caroline
Tong Jason
Weitzman Rachel
Mahanian Michelle
Tse Stephen
Magpantay Larry
Liu Philip T
Lourenco Elaine
Eskin Ascia
Liu Guanghao
Tse Eric
Chattopadhay Madhuri
La Cava Antonio
Fiala Milan
Martinez-Maza Otoniel
Rosenthal Mark J
Wiedau-Pazos Martina
author_sort Sayre James
title IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
title_short IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
title_full IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
title_fullStr IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
title_full_unstemmed IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients
title_sort il-17a is increased in the serum and in spinal cord cd8 and mast cells of als patients
publisher BMC
series Journal of Neuroinflammation
issn 1742-2094
publishDate 2010-11-01
description <p>Abstract</p> <p>The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent assays (ELISAs) to measure the cytokine interleukin-17A (IL-17A) in the serum of ALS patients (n = 32; 28 sporadic ALS (sALS) and 4 familial ALS (fALS)) and control subjects (n = 14; 10 healthy subjects and 4 with autoimmune disorders). IL-17A serum concentrations were 5767 ± 2700 pg/ml (mean ± SEM) in sALS patients and 937 ± 927 pg/ml in fALS patients in comparison to 7 ± 2 pg/ml in control subjects without autoimmune disorders (p = 0.008 ALS patients vs. control subjects by Mann-Whitney test). Sixty-four percent of patients and no control subjects had IL-17A serum concentrations > 50 pg/ml (p = 0.003 ALS patients vs. healthy subjects by Fisher's exact test). The spinal cords of sALS (n = 8), but not control subjects (n = 4), were infiltrated by interleukin-1β- (IL-1β-), and tumor necrosis factor-α-positive macrophages (co-localizing with neurons), IL-17A-positive CD8 cells, and IL-17A-positive mast cells. Mononuclear cells treated with aggregated forms of wild type superoxide dismutase-1 (SOD-1) showed induction of the cytokines IL-1β, interleukin-6 (IL-6), and interleukin-23 (IL-23) that may be responsible for induction of IL-17A. In a microarray analysis of 28,869 genes, stimulation of peripheral blood mononuclear cells by mutant superoxide dismutase-1 induced four-fold higher transcripts of interleukin-1α (IL-1α), IL-6, CCL20, matrix metallopeptidase 1, and tissue factor pathway inhibitor 2 in mononuclear cells of patients as compared to controls, whereas the anti-inflammatory cytokine interleukin-10 (IL-10) was increased in mononuclear cells of control subjects. Aggregated wild type SOD-1 in sALS neurons could induce in mononuclear cells the cytokines inducing chronic inflammation in sALS spinal cord, in particular IL-6 and IL-17A, damaging neurons. Immune modulation of chronic inflammation may be a new approach to sALS.</p>
url http://www.jneuroinflammation.com/content/7/1/76
work_keys_str_mv AT sayrejames il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT koopatrick il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT chotiffany il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT nguyencaroline il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT tongjason il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT weitzmanrachel il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT mahanianmichelle il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT tsestephen il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT magpantaylarry il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT liuphilipt il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT lourencoelaine il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT eskinascia il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT liuguanghao il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT tseeric il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT chattopadhaymadhuri il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT lacavaantonio il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT fialamilan il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT martinezmazaotoniel il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT rosenthalmarkj il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
AT wiedaupazosmartina il17aisincreasedintheserumandinspinalcordcd8andmastcellsofalspatients
_version_ 1725542603819057152